<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04242758</url>
  </required_header>
  <id_info>
    <org_study_id>PURITY - Protcol 5</org_study_id>
    <nct_id>NCT04242758</nct_id>
  </id_info>
  <brief_title>Phthalates Exposure in Type 2 Diabetic Patients and Diuretic Therapy</brief_title>
  <acronym>PURITY</acronym>
  <official_title>Exploring the Association Between Phthalates Exposure, Measured Through Their Urinary Metabolites, and Renal Function Impairment in Individuals With TYpe 2 Diabetes - SGLT2 Subprotocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pisa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pisa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this open clinical trial, 30 subjects with inadequately controlled T2D and eligible, as
      per good clinical practice, for therapy with SGLT-2 inhibitor, will be randomized to receive
      a SGLT-2 inhibitor vs other oral-antidiabetic drugs (OADs) therapy for 3 months. Measures
      will be performed at baseline, after 2 days, after one month and at the end of the study
      protocol, as per good clinical practice
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Total concentrations of MEHP, MEOHP and MEHHP will be quantified, in the laboratories of
           the Institute of Clinical Physiology, National Research Council, Pisa, in a spot morning
           urine sample by ultra-HPLC coupled with electrospray ionization/quadrupole
           time-of-flight mass spectrometry (Agilent UHPLC 1290 infinity coupled to an Agilent 6540
           MS-QTOF, Santa Clara, CA) using stable isotope labeled substrates, i.e. MEHP
           (ring-1,2-13C2, dicarboxyl-13C2), MEHHP, MEHHP 13C4, MEOHP and MEOHP 13C4 that will be
           purchased from Cambridge Isotope Laboratories (Tewksbury, MA).

        -  Urinary creatinine concentrations will be measured to adjust urinary concentrations of
           DEHP metabolite (Beckman Coulter AU400, Brea, CA), thus minimizing the inﬂuence of urine
           volume.

        -  Serum and urinary inflammatory markers and adipocytokines will be quantitatively
           determined using sandwich enzyme-linked immunosorbent assays kits according to the
           manufacturer's instructions. Optical density will be measured using a microplate reader.

        -  Serum and urinary markers of oxidative stress will be measured by gold standard
           techniques. In detail, MDA will be quantified by TBARS reactive substances measured by
           optical density; GSH-Px by a specific assay kit according to the manufacturer's
           instruction; SOD activity will be determined using a specific SOD kit; urinary
           8-isoprostane concentration will be measured by a specific affinity sorbent. (Cayman
           Chemical, Ann Harbor, MI, USA) according to the manufacturer's instructions.

        -  To analyze mitochondrial DNA we will apply a triplex design previously reported to
           amplify mitochondria loci located within the MinorArc and MajorArc, respectively. To
           assess nuclear DNA, we will use RNase P Copy Number Reference.

        -  The phthalates-free diet will be self-administered by the individuals under
           intervention, following a set of instruction and rules provided by the physicians based
           on the current literature data.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 4, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Phthalates concentration</measure>
    <time_frame>Changes between baseline and 1 month</time_frame>
    <description>Exposure to phthalates assessed through urinary concentration of phthalates metabolites spot and 24-hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary Phthalates concentration</measure>
    <time_frame>Changes between baseline and 3 month</time_frame>
    <description>Exposure to phthalates assessed through urinary excretion spot and 24-hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>1 and 3 months</time_frame>
    <description>Fasting glucose measured in a fasting morning blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated Haemoglobin</measure>
    <time_frame>1 and 3 months</time_frame>
    <description>HbA1c in a fasting measured in a morning blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>1 and 3 months</time_frame>
    <description>Using creatinine measured in a fasting morning blood sample and estimated by eGFR (calculated with the CDK-EPI formula)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macrovascular events</measure>
    <time_frame>1 and 3 months</time_frame>
    <description>Number of participants with MACE events (Stroke, Acute Myocardial Infarction, Unstable Angina, Revascularization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin excretion</measure>
    <time_frame>1 and 3 months</time_frame>
    <description>Measured by urinary albumin/creatinine ratio</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Renal Function Disorder</condition>
  <condition>Glucose Metabolism Disorders</condition>
  <arm_group>
    <arm_group_label>Dapaglifozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>People undergoing SGLT2i (Dapaglifozin) therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrochlorothiazide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>People undergoing thiazide (Hydrochlorothiazide) therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10 MG</intervention_name>
    <description>SGLT2-inhibitor: Diabetic oral drug with diuretic properties</description>
    <arm_group_label>Dapaglifozin</arm_group_label>
    <other_name>DAPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide 12.5mg</intervention_name>
    <description>Best known thiazide class diuretic.</description>
    <arm_group_label>Hydrochlorothiazide</arm_group_label>
    <other_name>HCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals of both sex;

          -  Age between 18 and 85 years;

          -  T2D

          -  T2D duration &gt; 6 months

          -  BMI ≤ 40 Kg/m2,

          -  HbA1c &gt; 48 mmol/mol

          -  Eligible for SGLT-2i therapy

        Exclusion criteria

          -  age &gt;85 years,

          -  eGFR &lt;60 ml/min/1.73 m2,

          -  occurring acute complications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Solini, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pisa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pisa</name>
      <address>
        <city>Pisa</city>
        <zip>56125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Dales RE, Kauri LM, Cakmak S. The associations between phthalate exposure and insulin resistance, β-cell function and blood glucose control in a population-based sample. Sci Total Environ. 2018 Jan 15;612:1287-1292. doi: 10.1016/j.scitotenv.2017.09.009. Epub 2017 Sep 8.</citation>
    <PMID>28898934</PMID>
  </reference>
  <reference>
    <citation>Lind PM, Zethelius B, Lind L. Circulating levels of phthalate metabolites are associated with prevalent diabetes in the elderly. Diabetes Care. 2012 Jul;35(7):1519-24. doi: 10.2337/dc11-2396. Epub 2012 Apr 12.</citation>
    <PMID>22498808</PMID>
  </reference>
  <reference>
    <citation>Mengozzi A, Carli F, Biancalana E, Della Latta V, Seghieri M, Gastaldelli A, Solini A. Phthalates Exposure as Determinant of Albuminuria in Subjects With Type 2 Diabetes: A Cross-Sectional Study. J Clin Endocrinol Metab. 2019 May 1;104(5):1491-1499. doi: 10.1210/jc.2018-01797.</citation>
    <PMID>30462244</PMID>
  </reference>
  <reference>
    <citation>Kato K, Silva MJ, Reidy JA, Hurtz D 3rd, Malek NA, Needham LL, Nakazawa H, Barr DB, Calafat AM. Mono(2-ethyl-5-hydroxyhexyl) phthalate and mono-(2-ethyl-5-oxohexyl) phthalate as biomarkers for human exposure assessment to di-(2-ethylhexyl) phthalate. Environ Health Perspect. 2004 Mar;112(3):327-30.</citation>
    <PMID>14998748</PMID>
  </reference>
  <reference>
    <citation>Hauser R, Meeker JD, Park S, Silva MJ, Calafat AM. Temporal variability of urinary phthalate metabolite levels in men of reproductive age. Environ Health Perspect. 2004 Dec;112(17):1734-40. Erratum in: Environ Health Perspect. 2004 Dec;112(17):1740.</citation>
    <PMID>15579421</PMID>
  </reference>
  <reference>
    <citation>Zota AR, Singla V, Adamkiewicz G, Mitro SD, Dodson RE. Reducing chemical exposures at home: opportunities for action. J Epidemiol Community Health. 2017 Jul 29. pii: jech-2016-208676. doi: 10.1136/jech-2016-208676. [Epub ahead of print]</citation>
    <PMID>28756396</PMID>
  </reference>
  <reference>
    <citation>Frederiksen H, Nielsen O, Koch HM, Skakkebaek NE, Juul A, Jørgensen N, Andersson AM. Changes in urinary excretion of phthalates, phthalate substitutes, bisphenols and other polychlorinated and phenolic substances in young Danish men; 2009-2017. Int J Hyg Environ Health. 2020 Jan;223(1):93-105. doi: 10.1016/j.ijheh.2019.10.002. Epub 2019 Oct 25.</citation>
    <PMID>31669154</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pisa</investigator_affiliation>
    <investigator_full_name>Anna Solini</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

